Drug Discovery Biology Laboratory, Monash Institute of Pharmaceutical Sciences and Department of Pharmacology, Monash University, Parkville, Victoria, Australia (C.K., D.W., J.S., A.C., P.M.S.); and Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Scottsdale, Arizona (L.J.M.).
Drug Discovery Biology Laboratory, Monash Institute of Pharmaceutical Sciences and Department of Pharmacology, Monash University, Parkville, Victoria, Australia (C.K., D.W., J.S., A.C., P.M.S.); and Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Scottsdale, Arizona (L.J.M.)
J Pharmacol Exp Ther. 2015 Apr;353(1):52-63. doi: 10.1124/jpet.114.220913. Epub 2015 Jan 28.
The glucagon-like peptide-1 receptor (GLP-1R) is a class B G protein-coupled receptor that has a critical role in the regulation of glucose homeostasis, principally through the regulation of insulin secretion. The receptor system is highly complex, able to be activated by both endogenous [GLP-1(1-36)NH2, GLP-1(1-37), GLP-1(7-36)NH2, GLP-1(7-37), oxyntomodulin], and exogenous (exendin-4) peptides in addition to small-molecule allosteric agonists (compound 2 [6,7-dichloro-2-methylsulfonyl-3-tert-butylaminoquinoxaline], BETP [4-(3-benzyloxy)phenyl)-2-ethylsulfinyl-6-(trifluoromethyl)pyrimidine]). Furthermore, the GLP-1R is subject to single-nucleotide polymorphic variance, resulting in amino acid changes in the receptor protein. In this study, we investigated two polymorphic variants previously reported to impact peptide-mediated receptor activity (M149) and small-molecule allostery (C333). These residues were mutated to a series of alternate amino acids, and their functionality was monitored across physiologically significant signaling pathways, including cAMP, extracellular signal-regulated kinase 1 and 2 phosphorylation, and intracellular Ca(2+) mobilization, in addition to peptide binding and cell-surface expression. We observed that residue 149 is highly sensitive to mutation, with almost all peptide responses significantly attenuated at mutated receptors. However, most reductions in activity were able to be restored by the small-molecule allosteric agonist compound 2. Conversely, mutation of residue 333 had little impact on peptide-mediated receptor activation, but this activity could not be modulated by compound 2 to the same extent as that observed at the wild-type receptor. These results provide insight into the importance of residues 149 and 333 in peptide function and highlight the complexities of allosteric modulation within this receptor system.
胰高血糖素样肽-1 受体(GLP-1R)是一种 B 类 G 蛋白偶联受体,在调节葡萄糖稳态方面起着关键作用,主要通过调节胰岛素分泌。该受体系统非常复杂,能够被内源性[GLP-1(1-36)NH2、GLP-1(1-37)、GLP-1(7-36)NH2、GLP-1(7-37)、oxyntomodulin]和外源性(exendin-4)肽以及小分子变构激动剂(化合物 2[6,7-二氯-2-甲基磺酰基-3-叔丁基氨基喹喔啉]、BETP[4-(3-苯甲氧基)苯基]-2-乙基磺酰基-6-(三氟甲基)嘧啶])激活。此外,GLP-1R 受到单核苷酸多态性变异的影响,导致受体蛋白中的氨基酸发生变化。在这项研究中,我们研究了先前报道的两种影响肽介导受体活性(M149)和小分子变构作用(C333)的多态变体。这些残基被突变为一系列替代氨基酸,并监测其在包括 cAMP、细胞外信号调节激酶 1 和 2 磷酸化以及细胞内 Ca2+动员在内的生理相关信号通路中的功能,此外还监测了肽结合和细胞表面表达。我们观察到,残基 149 对突变非常敏感,突变受体的几乎所有肽反应都显著减弱。然而,大多数活性降低都可以通过小分子变构激动剂化合物 2 得到恢复。相反,残基 333 的突变对肽介导的受体激活几乎没有影响,但这种活性不能像在野生型受体中那样被化合物 2 同等程度地调节。这些结果深入了解了残基 149 和 333 在肽功能中的重要性,并强调了该受体系统中变构调节的复杂性。